Literature DB >> 2999248

Macrophage cytotoxicity: interleukin 1 as a mediator of tumor cytostasis.

D Lovett, B Kozan, M Hadam, K Resch, D Gemsa.   

Abstract

Purified macrophage interleukin 1 (IL 1) induced a concentration-dependent inhibition of the proliferation of two commonly used tumor cell target lines, the human myeloid K562 and the murine T lymphoma Eb. In contrast, mastocytoma-derived P815 cells were not inhibited. The cytostatic action of IL 1 was not associated with direct cytotoxicity and was only partially reversible. PGE or interferon did not appear to mediate these effects. IL 1 treatment of the multipotential K562 cells revealed no morphologic evidence for the induction of specific differentiation. FACS analysis of IL 1-treated K562 cells showed a rapid decrease in transferrin receptor density, and a more delayed, but highly significant, increase in HLA-A,B,C antigen density. These findings provide one explanation for the frequently reported macrophage cytostatic actions against tumor cells, and indicate as well that IL 1, like interferon, may enhance the expression of Class I MHC antigens. These observations further extend the range of IL 1 actions and underscore the fundamental and direct role of this monokine in macrophage antitumor activity.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2999248

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  30 in total

1.  Cachectin/tumor necrosis factor regulates hepatic acute-phase gene expression.

Authors:  D H Perlmutter; C A Dinarello; P I Punsal; H R Colten
Journal:  J Clin Invest       Date:  1986-11       Impact factor: 14.808

2.  Activation of macrophages in an experimental rat model of arthritis induced by Erysipelothrix rhusiopathiae infection.

Authors:  H Renz; U Gentz; A Schmidt; T Dapper; M Nain; D Gemsa
Journal:  Infect Immun       Date:  1989-10       Impact factor: 3.441

Review 3.  Secretory products of macrophages.

Authors:  C F Nathan
Journal:  J Clin Invest       Date:  1987-02       Impact factor: 14.808

Review 4.  [Hematologic or hemostaseologic "paraneoplastic syndromes" as prognostic factors?].

Authors:  W Schneider
Journal:  Klin Wochenschr       Date:  1988-02-01

5.  Existence of both IL-1 alpha and beta in normal human amniotic fluid: unique high molecular weight form of IL-1 beta.

Authors:  T Tamatani; H Tsunoda; H Iwasaki; M Kaneko; T Hashimoto; K Onozaki
Journal:  Immunology       Date:  1988-11       Impact factor: 7.397

6.  Mechanism of anaemia in rheumatoid arthritis: demonstration of raised interleukin 1 beta concentrations in anaemic patients and of interleukin 1 mediated suppression of normal erythropoiesis and proliferation of human erythroleukaemia (HEL) cells in vitro.

Authors:  C P Maury; L C Andersson; A M Teppo; S Partanen; E Juvonen
Journal:  Ann Rheum Dis       Date:  1988-12       Impact factor: 19.103

7.  Tumor necrosis factor mediates endotoxic effects in mice.

Authors:  F Bauss; W Dröge; D N Männel
Journal:  Infect Immun       Date:  1987-07       Impact factor: 3.441

8.  Anti-(tumor necrosis factor) alters the response of human monocytes to liposomal muramyl tripeptide.

Authors:  M Maeda; T Asano; E S Kleinerman
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

9.  The production of interleukin-1 receptor antagonist by human bronchogenic carcinoma.

Authors:  D R Smith; S L Kunkel; T J Standiford; S W Chensue; M W Rolfe; M B Orringer; R I Whyte; M D Burdick; J M Danforth; A R Gilbert
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

10.  Growth inhibition of tumour cells by a liposome-encapsulated, mycolic acid-containing glycolipid, trehalose 2,3,6'-trimycolate.

Authors:  Y Ohtsubo; M Furukawa; T Imagawa; N Sugimoto; M Ikutoh; S Nakatsugi; Y Katoh; S Shinka; Y Dohi
Journal:  Immunology       Date:  1991-11       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.